Provided is a novel medical composition capable of promoting fibrinolysis. The medical composition for promoting fibrinolysis contains edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of those. In addition to edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of those, the medical composition for promoting fibrinolysis further contains a TAFIa inhibitor.